Skip to main content

Pairings: Apr 22, 2009

Premium

Frank Witney has left his positions at Affymetrix as executive VP and chief commercial officer to serve as president and CEO of the chemical chromatography systems maker Dionex. He replaces Lukas Braunschweiler, who has been president and CEO of Dionex since 2002. Braunschweiler left the post to serve as president and CEO of Ruag Holding.

Witney was president of drug discovery tools at PerkinElmer and he was president and CEO of Panomics before it was purchased last year by Affymetrix.


Mitrionics, a developer of parallel processing software and accelerated hybrid computing servers, has appointed Dietrich Stephan as its first scientific advisory board member.

Stephan is the co-founder and chief science officer for the consumer genomics firms Navigenics, chairman of the National Institutes of Health Neuroscience Microarray Consortium, and founding chairman of the neurogenomics division of the Translational Genomics Research Institute.


Karine Hovanes has joined Combimatrix Molecular Diagnostics as its new laboratory director. Prior to joining Combimatrix, Hoyanes was assistant lab director of US Labs, now a part of Laboratory Corporation of America.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.